UroGen Pharma (URGN) Competitors $10.39 +0.46 (+4.63%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends URGN vs. AVDL, BCYC, ZYME, SEPN, NUVB, PSTX, COLL, GYRE, COGT, and QUREShould you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Avadel Pharmaceuticals (AVDL), Bicycle Therapeutics (BCYC), Zymeworks (ZYME), Septerna (SEPN), Nuvation Bio (NUVB), Poseida Therapeutics (PSTX), Collegium Pharmaceutical (COLL), Gyre Therapeutics (GYRE), Cogent Biosciences (COGT), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry. UroGen Pharma vs. Avadel Pharmaceuticals Bicycle Therapeutics Zymeworks Septerna Nuvation Bio Poseida Therapeutics Collegium Pharmaceutical Gyre Therapeutics Cogent Biosciences uniQure Avadel Pharmaceuticals (NASDAQ:AVDL) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk. Which has more risk and volatility, AVDL or URGN? Avadel Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Do analysts rate AVDL or URGN? Avadel Pharmaceuticals currently has a consensus target price of $21.00, suggesting a potential upside of 157.35%. UroGen Pharma has a consensus target price of $43.70, suggesting a potential upside of 320.60%. Given UroGen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe UroGen Pharma is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00UroGen Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media refer more to AVDL or URGN? In the previous week, Avadel Pharmaceuticals had 31 more articles in the media than UroGen Pharma. MarketBeat recorded 35 mentions for Avadel Pharmaceuticals and 4 mentions for UroGen Pharma. UroGen Pharma's average media sentiment score of 1.36 beat Avadel Pharmaceuticals' score of 0.11 indicating that UroGen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 10 Negative mention(s) 1 Very Negative mention(s) Neutral UroGen Pharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, AVDL or URGN? UroGen Pharma has lower revenue, but higher earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$138.16M5.69-$160.28M-$0.79-10.33UroGen Pharma$89.36M2.73-$102.24M-$3.15-3.30 Does the MarketBeat Community believe in AVDL or URGN? UroGen Pharma received 20 more outperform votes than Avadel Pharmaceuticals when rated by MarketBeat users. Likewise, 73.94% of users gave UroGen Pharma an outperform vote while only 66.28% of users gave Avadel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAvadel PharmaceuticalsOutperform Votes34666.28% Underperform Votes17633.72% UroGen PharmaOutperform Votes36673.94% Underperform Votes12926.06% Is AVDL or URGN more profitable? Avadel Pharmaceuticals has a net margin of -52.53% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-52.53% -93.34% -44.77% UroGen Pharma -129.11%N/A -47.94% Do insiders and institutionals have more ownership in AVDL or URGN? 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 4.8% of Avadel Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of UroGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryUroGen Pharma beats Avadel Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUroGen PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$243.69M$6.56B$5.28B$9.00BDividend YieldN/A2.91%5.08%4.01%P/E Ratio-3.3010.1488.8517.19Price / Sales2.73180.901,152.44127.67Price / CashN/A57.6343.2037.77Price / Book-3.744.995.165.03Net Income-$102.24M$153.75M$122.10M$228.41M7 Day Performance-5.89%-4.14%-2.09%-0.38%1 Month Performance-8.46%-2.23%-0.22%1.58%1 Year Performance-28.79%-2.79%24.47%16.79% UroGen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUroGen Pharma4.0653 of 5 stars$10.39+4.6%$43.70+320.6%-31.9%$243.69M$89.36M-3.30200Analyst ForecastNews CoveragePositive NewsGap UpAVDLAvadel Pharmaceuticals3.6034 of 5 stars$10.69-3.3%$24.43+128.5%-45.6%$1.03B$138.16M-13.53154Analyst ForecastAnalyst RevisionNews CoverageGap UpBCYCBicycle Therapeutics3.2337 of 5 stars$14.88-0.1%$35.25+136.9%-19.7%$1.03B$36.90M-4.52240Analyst ForecastShort Interest ↑Gap UpZYMEZymeworks3.7804 of 5 stars$14.46-3.7%$19.17+32.5%+25.2%$995.98M$62.20M-9.64290Insider TradeGap UpSEPNSepterna2.2051 of 5 stars$22.09-6.8%$43.67+97.7%N/A$980.86M$981,000.000.00N/ANUVBNuvation Bio2.2983 of 5 stars$2.83-2.1%$6.60+133.2%+64.6%$952.49M$2.16M-1.3060Short Interest ↑Gap DownPSTXPoseida Therapeutics3.6605 of 5 stars$9.56+0.4%$9.50-0.6%N/A$934.72M$150.86M-15.17260COLLCollegium Pharmaceutical4.1916 of 5 stars$28.62-3.0%$42.60+48.8%+2.1%$923.00M$599.25M12.34210Insider TradeGYREGyre Therapeutics0.2859 of 5 stars$9.73-9.8%N/A-53.3%$909.96M$105.03M0.0040Short Interest ↑COGTCogent Biosciences1.4452 of 5 stars$8.06+2.3%$14.83+84.0%+45.7%$890.32MN/A-3.2580Analyst ForecastShort Interest ↑News CoverageGap UpQUREuniQure3.8778 of 5 stars$18.08+0.8%$33.88+87.4%+114.1%$881.27M$28.59M-3.65500Short Interest ↓Gap Up Related Companies and Tools Related Companies Avadel Pharmaceuticals Competitors Bicycle Therapeutics Competitors Zymeworks Competitors Septerna Competitors Nuvation Bio Competitors Poseida Therapeutics Competitors Collegium Pharmaceutical Competitors Gyre Therapeutics Competitors Cogent Biosciences Competitors uniQure Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:URGN) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free URGN Stock Alerts